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Edited by Jacomine Krijnse-LockerAbstract A lens epithelium-derived growth factor (LEDGF)/
p75 peptide was evaluated for human immunodeﬁciency virus
type 1 integrase (IN) inhibitory activity. The LEDGF/p75 pep-
tide modestly inhibited IN catalysis and was dependent on IN–
DNA assembly. The peptide was also eﬀective at disrupting
LEDGF/p75–IN complex formation. We next investigated the
activity of the LEDGF/p75 peptide on IN mutant proteins that
are unable to catalyze the DNA strand transfer reaction. The
LEDGF/p75 peptide displayed an increased potency on these
IN proteins, from 5-fold to greater than 10-fold, indicating the
IN multimeric state greatly inﬂuences the peptide inhibitory ef-
fects. These results shed light on IN–DNA multimeric formation,
and how this process inﬂuences the LEDGF/p75–IN interaction.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Human immunodeﬁciency virus type 1 (HIV-1) integrase
(IN) is an essential enzyme for viral replication, and mediates
the insertion of viral DNA within the host cell genome via two
successive DNA reaction events. Initially, IN cleaves a dinucle-
otide oﬀ the 3 0-termini of the reverse transcribed viral DNA.
This step occurs in the cytosol and is referred to as 3 0-process-
ing. Next, following migration of the IN–viral DNA complex
to the nucleus in the context of a large nucleo-protein assembly
called the pre-integration complex, IN inserts the processed
viral DNA into the cellular genome. This DNA insertion event
is also known as the strand transfer process [1]. The DNA cut
and paste reactions mediated by IN can be performed in vitro
using isolated systems that contain puriﬁed protein, Mg2+ or
Mn2+ as a metal cofactor, and a DNA oligonucleotide sub-
strate with ends mimicking the U3 or U5 viral DNA termini
[2].
With the early advent of a convenient in vitro IN enzymatic
assay, the ﬁeld of IN drug design and discovery has largely fo-Abbreviations: HIV-1, human immunodeﬁciency virus type 1; IN,
integrase; WT, wild-type; LEDGF, lens epithelium-derived growth
factor; IBD, integrase binding domain
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doi:10.1016/j.febslet.2008.02.076cused on the development of compounds that directly inhibit
catalytic activity. These in vitro eﬀorts have produced some
notable successes, including the strand transfer speciﬁc inhibi-
tors MK-0518 [3,4] and GS-9137 [5], the former being the ﬁrst
US FDA approved drug targeting IN. Integration in vivo,
however, depends on multiple functional interactions between
IN and diﬀerent host cell cofactors [6]. The disruption of direct
cofactor-IN protein–protein interactions that are essential for
viral replication represent a new strategy for the design and
development of anti-HIV/AIDS therapeutics [7].
The transcriptional activator lens epithelium-derived growth
factor (LEDGF)/p75 is a pro-survival protein that plays a role
in the delicate balance between cell survival and apoptosis. The
protein is closely associated with condensed chromatin in the
nucleus [8], and activates the transcription of stress related/
anti-apoptotic proteins, thereby promoting cell growth and
protecting cells against stress-induced cell death [9]. LEDGF/
p75 is an essential HIV-1 IN cellular cofactor for viral replica-
tion [10,11]. The cellular protein acts as a chromatin tethering
factor to facilitate the interaction between IN and nuclear
chromatin [12,13]. LEDGF/p75 also directs viral DNA inte-
gration, biasing integration into AT-rich DNA transcriptional
units of the cellular genome [14,15]. The interacting domains
between LEDGF/p75 and IN have been cocrystalized (PDB
2B4J) [16], greatly enhancing the rational drug design of pro-
tein–protein disrupting anti-retroviral therapeutics targeting
IN. Here, we examined the biological activity of the
LEDGF/p75 derived peptide, 355IHAEIKNSLKIDNLDVN-
RCIEAL377, which contains two IN interacting residues
(I365 and D366) ﬁrst identiﬁed in the IN binding domain
(IBD) solution structure [17]. The peptide exhibited modest
inhibitory IN activity that was completely dependent on the
state of IN–DNA complex formation. The peptide also dis-
rupted LEDGF/p75–IN complex formation. Lastly, the
LEDGF/p75 peptide displayed a 5-fold to greater than 10-fold
increase in potency when tested against IN mutant proteins
unable to catalyze the strand transfer process; an enzymatic
activity that requires a tetrameric arrangement of IN, stabi-
lized by DNA binding at the dimer–dimer interface [18,19].2. Materials and methods
2.1. Expression and puriﬁcation of recombinant HIV-1 Integrase
The IN plasmid for wild-type (WT) and each mutant protein was
expressed in Escherichia coli BL21(De3) PLYS S expression strain
(Invitrogen) after induction by IPTG (1 mM) at an absorbance of
0.6–0.8 optical density at 595 nm. The culture was allowed to grow
for an additional 3–4 h at 37 C. This was followed by centrifugationblished by Elsevier B.V. All rights reserved.
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20 min. Cell lysis, Ni-aﬃnity chromatography puriﬁcation and dialysis
were performed as detailed in [20].
2.2. LEDGF/p75–IN AlphaScreen assay
The AlphaScreen assay was performed according to the manufac-
turers protocol (Perkin–Elmer, Benelux). Reactions were performed
in 25 ll ﬁnal volume in 384-well Optiwell microtiter plates (Perkin–
Elmer). The reaction buﬀer contained 25 mM Tris–HCl (pH 7.4),
150 mM NaCl, 1 mM MgCl2, 0.01% (v/v) Tween-20 and 0.1% (w/v)
bovine serum albumin. His6-tagged integrase (300 nM ﬁnal concentra-
tion) was incubated with the inhibitory peptide for 30 min at 4 C. The
peptide was added in varying concentrations spanning a wide range
from 0.2 lg/ml up to 2000 lg/ml. Afterwards 100 nM Flag-LEDGF/
p75 was added and incubation was prolonged for an additional hour
at 4 C. Subsequently, 5 ll of Ni-chelate–coated acceptor beads and
5 ll anti-Flag donor beads were added to a ﬁnal concentration of
20 lg/ml of both beads. Proteins and beads were incubated for 1 h at
30 C in order to allow association to occur. Exposure of the reaction
to direct light was omitted as much as possible and the emission of
light from the acceptor beads was measured in the EnVision plate read-
er (Perkin–Elmer) and analyzed using the EnVision manager software.3. Results
The binding domains between HIV-1 IN and the cellular
cofactor LEDGF/p75 contain a contact hotspot between
I365 of LEDGF/p75 with W132 and M178 (in addition to
T174, L102, A128, and A129) of IN. Shown in Fig. 1 is a mod-
iﬁed version of the cocrystal structure (PDB 2B4J) depicting
this protein–protein hotspot and highlighting the proximity
of the pertinent LEDGF/p75 peptide (355–377) with the WT
IN amino acid positions at the dimeric interface substituted
in this study. The crystal structure used here contained the
F185K substitution. To generate Fig. 1, we used the mutagen-
esis function in the molecular viewing program PYMOL (W.L.
DeLano, www.pymol.org) to revert position 185 back to the
WT phenylalanine residue. The addition of LEDGF/p75 has
been shown to stimulate strand transfer activity in vitro [21].
Currently it is unclear if the cellular protein has a stimulatoryFig. 1. LEDGF/p75–IN hotspot highlighting the LEDGF/p75 peptide
(355–377) and the four-tiered p electron orbital interaction at the IN
dimeric interface (PDB 2B4J). IN monomer A shown in yellow,
monomer B in magenta; amino acid residues shown in stick represen-
tation, with atom colors: C (green), N (blue), and S (orange); LEDGF/
p75 peptide (355–377) shown in cyan.or minimizing eﬀect on the aﬃnity of IN to bind naked DNA
in vitro [22,23], although a recent study supports on overall
stimulatory eﬀect when using reconstituted polynucleosome
associated DNA [24]. With these previous results in mind,
we sought to determine the in vitro activity of the LEDGF/
p75 peptide 355IHAEIKNSLKIDNLDVNRCIEAL377 on IN
enzymatic activity. The peptide was synthesized and deter-
mined to be 97.8% pure based on C18 reverse phase HPLC,
and the peptides mass was conﬁrmed to be 2622 amu after
mass spectrometric analysis (depicted in supplementary
Fig. 1A and B). We retained nine (355–364) and 12 (366–
377) amino acid residues on either side of I365 in order to pro-
mote proper secondary a-helical folding of the peptide. The
peptide was dissolved in water for all experiments after the he-
lix-promoting solvent triﬂuoroethanol was found to abolish IN
enzymatic activity.
Results indicate the peptide exhibits no stimulatory eﬀects
on IN enzymatic activity. No LEDGF/p75 peptide stimulatory
eﬀects on IN enzymatic activity were observed at peptide con-
centrations as high as 1 mM, and IN protein concentrations as
low as 0.2 lM (data not shown). The LEDGF/p75 peptide did
however inhibit IN catalytic activity in the presence of both
Mg2+ (data not shown) and Mn2+. IN catalytic activity proved
to be more robust in the presence of Mn2+ as opposed to
Mg2+. Mn2+ was therefore used for all subsequent in vitro
IN inhibitory experiments. Peptide IC50 values were
165 ± 28 lM and 153 ± 28 lM, for WT 3 0-processing and
strand transfer, respectively. The peptide was similarly active
against 3 0-processed DNA substrates, with an IC50 value of
167 ± 31 lM for the strand transfer activity. We also found
the order of addition did not aﬀect the peptides inhibitory
activity (incubation of peptide and DNA ﬁrst, followed by
addition of IN). We then examined the activity of the
LEDGF/p75 peptide against pre-assembled wild-type IN–
DNA complexes in the presence of Ca2+. Ca2+ is known to
promote IN–DNA complex formation without proceeding to
enzymatic cleavage of the DNA [25,26]. Following Ca2+ in-
duced IN–DNA pre-assembly, the subsequent addition of
Mg2+ or Mn2+ initiates IN catalysis. The peptide was com-
pletely ineﬀective against pre-assembled IN–DNA complexes.
Depicted in Fig. 2 is a gel comparison of the peptide inhibitory
eﬀects on WT IN in the presence of both Mn2+ and Ca2+ (fol-
lowed by Mn2+ induced catalysis). The LEDGF/p75 peptide
can be further utilized for the design of more potent peptidom-
imetic small molecule inhibitors.
Considering the peptide represents one contact hotspot be-
tween LEDGF/p75 and IN, we wondered whether it is capable
of disrupting the LEDGF/p75–IN interaction. Therefore we
analyzed its eﬀect on LEDGF/p75–IN complex formation of
the recombinant proteins by AlphaScreen [10,27]. This bead
based technology allows quantifying protein–protein interac-
tions and the respective inhibition by small molecules or pep-
tides targeting the interaction. In an initial cross-titration
experiment the optimal concentration to measure the
LEDGF/p75–IN interaction was determined to be 100 nM
LEDGF/p75 and 300 nM IN (data not shown). We then pre-
incubated IN with the peptide at increasing concentrations
prior to the addition of LEDGF/p75 and subsequent Alpha-
Screen analysis. The peptide disrupted LEDGF/p75–IN bind-
ing with an IC50 value of 25 lM. Depicted in Fig. 3 is the
inhibitory proﬁle of the peptide for LEDGF/p75–IN disrup-
tion with the raw AlphaScreen data listed in Table 1.
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Fig. 2. The LEDGF/p75 peptide IN inhibitory activity is dependent
on IN-DNA complex formation. Comparison of LEDGF/p75 peptide
activity against WT IN before (Mn2+) and after (Ca2+) IN-DNA
assembly. Inhibitory concentrations of the peptide decrease from
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Fig. 3. The LEDGF/p75 peptide 355IHAEIKNSLKIDNLDVNRCI-
EAL377 is eﬀective at disrupting LEDGF/p75–IN complex formation
at an IC50 value of 25 lM.
Table 1
LEDGF/p75 peptide AlphaScreen data for disruption of LEDGF/
p75–IN complex formation
LEDGF/p75 peptide
concentration
AlphaScreen
counts
Percent
inhibitiona (%)
No peptide 247588.2 0
0.076 lM 250817 0
0.76 lM 291803.5 0
7.6 lM 169826 30.72
76 lM 77618 68.33
760 lM 18359 92.5
Control 2455.5 NAb
aNormalized for background signal.
bNot applicable.
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Fig. 4. The four-tiered p electron orbital interaction at IN positions
W132, M178, F181, and F185 at the dimeric interface is critical for
strand transfer catalysis. STP refers to strand transfer products.
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tron orbital interaction at the IN dimeric interface that isessential only for the strand transfer activity of the viral en-
zyme, and not 3 0-processing [20]. Further studies revealed the
electron orbital interaction is four-tiered and involves IN resi-
dues W132, M178, F181, and F185. Results from our lab have
shown that disruption of the four-tiered electron interaction,
through the systematic introduction of non-conservative sub-
stitutions, terminates strand transfer activity, without abolish-
ing 3 0-processing catalysis (unpublished). Enzymatic activity of
each IN mutant protein is depicted in Fig. 4. Each mutant pro-
tein, with the exception of M178C (30% of WT) and F181G
(60% of WT), catalyzed 3 0-processing comparable to WT.
Disruption of the electron interaction does inﬂuence the
mechanics of 3 0-processing, as indicated by an increase in aber-
rant 20-mer and 18-mer cleavage products. However, no sig-
niﬁcant cleavage products are observed below this size
indicating the phenomenon is not an artifact of bacterial exo-
nuclease contamination. A complete in vitro and in vivo char-
acterization of each mutant IN protein is provided in an
upcoming manuscript by our group. The activity proﬁle of
the IN mutant enzymes indicate an intact p electron orbital
interaction at the dimeric interface is critical for the formation
of IN tetrameric–DNA ternary complexes, a requirement for
strand transfer catalysis. The interaction bridges the IN di-
meric interface and directly corresponds with the LEDGF/
p75–IN hotspot represented by our inhibitory peptide
(Fig. 1). The availability of IN mutants that uncouple the suc-
cessive enzymatic activities of the protein provided us with a
unique opportunity to study how the multimeric state of IN
with DNA substrate aﬀects the biological proﬁle of the
LEDGF/p75 peptide.
The LEDGF/p75 peptide gave striking results against our p
electron orbital interaction IN mutants. We found that IN
proteins deﬁcient in the non-covalent interaction were drasti-
cally more susceptible to peptide inhibition for 3 0-processing
only. A representative gel showing this preferential inhibition
is depicted in Fig. 5. The LEDGF/p75 peptide did not stimu-
late or restore the strand transfer activity of these proteins,
and therefore the inhibitory activity on this IN function could
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Fig. 5. IN proteins deﬁcient for the p electron orbital interaction at the dimeric interface are drastically more susceptible to LEDGF/p75 peptide 3 0-
processing inhibition. Peptide concentrations are given in micromolar. STP refers to strand transfer products.
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given in Table 2, with the results depicted in Fig. 6. The 3 0-pro-
cessing susceptibility index for each mutant is also given in
Table 2, which was calculated based on the fold reduction of
the 3 0-processing peptide IC50 value for each mutant in com-
parison to WT. Concerning 3 0-processing, W132G displayed
the most modest susceptibility of all the mutants deﬁcient inTable 2
LEDGF/p75 peptide IC50 values (lM) for IN proteins with suscep-
tibility indexa for mutant proteins
IN Protein 3 0-Processing Strand transfer Susceptibility index
WT 165 ± 28 153 ± 28 NAb
W132G 30 ± 11 NA 5.5
W132Y 14 ± 6 NA 11.8
W132F 67 ± 18 107 ± 25 2.5
M178C 18 ± 9 NA 9.2
F181G 14 ± 6 NA 11.8
F181Y 132 ± 19 154 ± 26 1.3
F185G 15 ± 7 NA 11
F185Y 151 ± 32 142 ± 36 1.1
aSusceptibility index calculated relative to WT 30-processing IC50
value.
bNot applicable.
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Fig. 6. The LEDGF/p75 peptide displays a 5-fold to greater than 10-
fold increase in 3 0-processing inhibition against p electron orbital
deﬁcient IN mutants. The LEDGF/p75 peptide inhibitory proﬁle
against all IN proteins under study; white bars represent 3 0-processing
IC50 values, whereas the black bars represent strand transfer IC50
values.the p electron orbital interaction with a ﬁve and a half-fold
reduction in peptide IC50 value as compared to WT. Substitut-
ing a tyrosine residue at position W132 created one of the two
most susceptible IN proteins towards 3 0-processing LEDGF/
p75 peptide inhibition, with a greater than 10-fold reduction
in IC50 value. The most conservative substitution, phenylala-
nine at position W132, where the non-covalent interaction is
intact and strand transfer activity is retained, exhibited only
a two and a half-fold reduction in 3 0-processing IC50 value
as compared to WT. The only substitution at position M178,
a conservative cysteine replacement, displayed slightly greater
than a 9-fold susceptibility towards LEDGF/p75 peptide 3 0-
processing inhibition, although this may be linked to a reduc-
tion in basal level catalytic activity of the protein. The non-
conservative F181G mutant protein is equal to W132Y as
the most susceptible protein towards 3 0-processing inhibition
under study, with a greater than 10-fold reduction in IC50 va-
lue for this function as compared to WT. The conservative
tyrosine substitution at position F181 displayed minor suscep-
tibility to 3 0-processing inhibition. Substitutions created at po-
sition F185 followed a similar pattern as compared with
position F181. The non-conservative glycine substitution at
this position exhibited an 11-fold susceptibility, whereas the
conservative tyrosine substitution was not overly susceptible
towards LEDGF/p75 peptide 3 0-processing inhibition. Con-
cerning strand transfer inhibition, only the mutants containing
conservative substitutions that restored the p electron orbital
interaction, and therefore strand transfer catalysis, could be as-
sessed for LEDGF/p75 peptide inhibition of this catalytic
activity. None of these IN mutants (W132F, F181Y, and
F185Y) displayed a drastic deviation for strand transfer IC50
values as compared to WT.4. Discussion
In this study we examined the biological activity of
the LEDGF/p75 peptide 355IHAEIKNSLKIDNLDVNRCI-
EAL377, derived from the IBD. We found the peptide to
exhibit inhibitory activity on IN catalysis. It appears that the
entire LEDGF/p75 protein may be required for strand transfer
stimulation, and the one LEDGF/p75–IN hotspot represented
L.Q. Al-Mawsawi et al. / FEBS Letters 582 (2008) 1425–1430 1429by our peptide is not suﬃcient for stimulation. This is in agree-
ment with previous reports on the biological activity of the
LEDGF/p75 IBD. It has been shown that the LEDGF/p75
IBD was unable to stimulate IN strand transfer activity, and
further competitively counteracted the stimulatory eﬀects of
the full length protein [28]. Additionally, the overexpression
of the LEDGF/p75 IBD inhibited HIV-1 replication [11,27].
A recent manuscript has also demonstrated the in vitro inhib-
itory eﬀects of two shorter LEDGF/p75 IBD derived peptides
(361–370 and 402–411) on IN catalysis. The LEDGF/p75 IBD
peptide 361–370 represents the center disordered loop region
(Fig. 1) contained in the longer LEDGF/p75 IBD peptide
355–377 examined in this study. Both peptides contain the
IN interacting residues I365 and D366. Unfortunately, this
group did not assay for the direct inhibition of the LEDGF/
p75–IN interaction. However, the shorter peptides reportedly
inhibited HIV integration and replication through an eﬀect
on IN multimerization [23]. If these results can be indepen-
dently reproduced, this would strengthen the use of LEDGF/
p75 IBD derived peptides as starting points to design pepti-
domimetic small molecule anti-HIV/AIDS therapeutics. Here
we show that the LEDGF/p75 peptide spanning residues
355–377 not only inhibits IN catalytic activity but also inhibits
the direct interaction between IN and LEDGF/p75 with an
IC50 value of 25 lM.
The LEDGF/p75 peptide was completely inactive when
tested against Ca2+ induced pre-assembled IN–DNA com-
plexes indicating the peptide may exert its inhibitory mecha-
nism of action by disrupting initial DNA binding to IN
necessary for 3 0-processing catalysis. A previous study exam-
ined the eﬀects of full length LEDGF/p75 on IN–DNA assem-
bly and catalytic activity of the viral enzyme. Whereas
LEDGF/p75 addition before 3 0-processing resulted in strand
transfer stimulation, no strand transfer activity enhancement
was observed when LEDGF/p75 was added after the 3 0-pro-
cessing catalytic step [29]. This observation indicates that the
presence of LEDGF/p75 during the formation of initial 3 0-pro-
cessing IN–DNA complexes, an IN dimeric catalytic process,
is further required to stimulate strand transfer catalysis, a tet-
rameric IN catalytic process. The authors present a sequential
model for LEDGF/p75–IN–DNA binding that involves pref-
erential LEDGF/p75–IN binding ﬁrst, followed by an en-
hanced IN–DNA ternary complex formation. Furthermore,
the model proposes that LEDGF/p75 would not exert any
strand transfer stimulation if IN were allowed to bind DNA
ﬁrst, due a defect in either the LEDGF/p75 binding of the
IN–DNA complex, or if binding did occur, an inability to
stimulate IN strand transfer catalysis [29]. The abolishment
of inhibitory activity of the LEDGF/p75 peptide (355–377)
against Ca2+ induced pre-assembled IN–DNA complexes sup-
port this sequential binding model.
We additionally evaluated the inhibitory eﬀects of the
LEDGF/p75 peptide against a panel of IN mutant proteins
from our laboratory. Current studies in our laboratory are
aimed at deﬁning the binding ability of the full length
LEDGF/p75 protein with our IN mutant proteins, and the ef-
fects the intact cellular protein may have on IN mutant catal-
ysis. The IN mutant proteins either contained an abolished or
restored p electron orbital interaction at the dimeric interface
of the protein, introduced systematically by conservative and
non-conservative amino acid substitutions, that we observed
to be essential for strand transfer catalysis alone (Fig. 4). Pre-vious studies have shown that an IN dimeric species is mini-
mally required for 3 0-processing, whereas a tetrameric
arrangement of IN, stabilized by DNA binding at the dimer–
dimer interface, is required for strand transfer [18,19]. A recent
kinetic study using avian sarcoma virus – HIV chimeric IN
proteins also found the 3 0-processing turnover rate was en-
hanced with a tetrameric species suggestive of a coupling
mechanism for 3 0-processing and strand transfer [30]. In line
with the model of DNA-induced stabilization of IN tetramers,
IN proteins containing an abolished p electron orbital interac-
tion at the dimeric interface are not capable of stabilizing the
DNA substrate at the dimer-dimer interface, and therefore tet-
ramerization. We found the LEDGF/p75 peptide was much
more eﬃcient at 3 0-processing inhibition, from 5-fold to great-
er than 10-fold, against IN mutants that were deﬁcient for the
p electron orbital interaction at the dimer interface, whereas
IN mutant proteins with the dimeric interaction restored dis-
played an inhibitory proﬁle similar to WT. We propose the
presence of the p electron orbital interaction at the IN dimeric
interface promotes initial DNA binding for 3 0-processing,
most likely somewhere along the length of the DNA substrate
away from the termini to be processed by the catalytic triad at
the IN active site. DNA binding proteins commonly interact
with DNA via p electron orbital stacking interactions between
aromatic amino acids and the bases of nucleic acids. IN pro-
teins that lack this non-covalent interaction were much more
susceptible to 3 0-processing inhibition by DNA binding inter-
ference of the LEDGF/p75 peptide. Following this hypothesis
it appears the impairment of initial DNA binding by IN pro-
teins that contain a disrupted four-tiered p electron orbital
interaction at the dimeric interface is not suﬃcient to abolish
3 0-processing, but is more than enough to abolish strand trans-
fer catalytic activity, possibly through a tenuous stabilization
of target DNA substrate at the dimer–dimer interface. The
explanation for these disparate observations most likely lies
in how IN tetramerization takes place, the mechanism by
which DNA is stabilized between IN dimers during this pro-
cess, and the mechanistic and structural role LEDGF/p75
plays during IN 3 0-processing and strand transfer catalysis.
In summary, we have demonstrated the inhibitory activity of
a LEDGF/p75 IBD derived peptide, and have unraveled its
inhibitory mechanism of action. The peptide displayed activity
against IN catalysis and was also eﬀective for the disruption of
LEDGF/p75–IN binding. The LEDGF/p75 peptide can fur-
ther be utilized to design more potent peptidomimetic small
molecule IN inhibitors to develop as HIV/AIDS therapeutics.
Lastly, by examining the inhibitory proﬁle of the peptide
against a series of IN mutants, we have additionally provided
insight into the mechanistic details of IN–DNA ternary com-
plex formation and how LEDGF/p75 aﬀects this process.
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